QMM for Pharmaceutical Manufacturers– Implications for Drug Manufacturers, API Suppliers and Contract Manufacturers
Facing ongoing challenges with drug shortages and quality problems, the pharmaceutical industry seeks robust solutions. FDA’s Quality Management Maturity (QMM) initiative offers a promising pathway. By focusing on four key pillars, including sustainability, risk management, regulatory compliance, and quality culture, the QMM initiative aims to elevate the entire manufacturing chain’s reliability and quality. Embracing these principles could not only reduce time and expenses but also make drug manufacturers, API suppliers, and CMO/CDMOs more attractive to regulators and the public. Dive into the details of how QMM is shaping the future of a stable and high-quality drug supply.
